Literature DB >> 1704638

Polysaccharide nature of O antigen in protective ribosomal preparations from Shigella: experimental evidence and implications for the ribosomal vaccine concept.

V I Levenson1, T P Egorova.   

Abstract

Shigella ribosomal vaccine (SRV) was previously shown to be highly active in induction of mucosal and systemic O-antibody response and protection against Shigella infection in guinea pigs and monkeys. In this study, the O-specific component (OSC) was isolated from the SRV by affinity chromatography using rabbit O antibodies coupled to CNBr-Sepharose. The results of the reaction with carbocyanine dye as well as chemical data show that ribosomal OSC is devoid of lipid A and KDO, which are characteristic of classical LPS. The comparison of OSC with various LPS-related substances led to the conclusion that ribosomal OSC is similar to and probably identical with cytoplasmic O polysaccharide (L hapten), an O-side-chain polymer which accumulates in cytoplasm. It is hypothesized that the extremely high immunogenicity of SRV depends on a cooperative action of OSC, representing an epitope-specific part of the vaccine, and a ribosomal particle which serves as a vector, providing amplification of the immunogenic effect. The data obtained indicate the presence of a non-covalent link between the two components of the ribosomal vaccine.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1704638     DOI: 10.1016/0923-2508(90)90065-x

Source DB:  PubMed          Journal:  Res Microbiol        ISSN: 0923-2508            Impact factor:   3.992


  2 in total

1.  Protective ribosomal preparation from Shigella sonnei as a parenteral candidate vaccine.

Authors:  V I Levenson; T P Egorova; Z P Belkin; V G Fedosova; J L Subbotina; E Z Rukhadze; E K Dzhikidze; Z K Stassilevich
Journal:  Infect Immun       Date:  1991-10       Impact factor: 3.441

2.  Protection against local Shigella sonnei infection in mice by parenteral immunization with a nucleoprotein subcellular vaccine.

Authors:  V J Levenson; C P Mallett; T L Hale
Journal:  Infect Immun       Date:  1995-07       Impact factor: 3.441

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.